Assembly Biosciences, Inc. (ASMB)
20.13
-0.73
(-3.50%)
USD |
NASDAQ |
Oct 30, 16:00
20.19
+0.06
(+0.30%)
After-Hours: 20:00
Assembly Biosciences Enterprise Value : 81.58M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 81.58M |
| October 29, 2026 | 96.07M |
| October 28, 2026 | 90.31M |
| October 27, 2026 | 84.95M |
| October 26, 2026 | 72.44M |
| October 23, 2026 | 75.82M |
| October 22, 2026 | 84.55M |
| October 21, 2026 | 88.13M |
| October 20, 2026 | 102.62M |
| October 19, 2026 | 82.17M |
| October 16, 2026 | 80.78M |
| October 15, 2026 | 90.31M |
| October 14, 2026 | 89.52M |
| October 13, 2026 | 85.74M |
| October 12, 2026 | 133.98M |
| October 09, 2026 | 149.07M |
| October 08, 2026 | 134.97M |
| October 07, 2026 | 137.55M |
| October 06, 2026 | 122.27M |
| October 05, 2026 | 133.38M |
| October 02, 2026 | 129.41M |
| October 01, 2026 | 138.15M |
| September 30, 2026 | 148.27M |
| September 29, 2026 | 148.07M |
| September 28, 2026 | 150.65M |
| Date | Value |
|---|---|
| September 25, 2026 | 151.85M |
| September 24, 2026 | 151.65M |
| September 23, 2026 | 157.80M |
| September 22, 2026 | 187.18M |
| September 21, 2026 | 186.98M |
| September 18, 2026 | 177.65M |
| September 17, 2026 | 185.00M |
| September 16, 2026 | 187.77M |
| September 15, 2026 | 200.28M |
| September 14, 2026 | 256.85M |
| September 11, 2026 | 273.53M |
| September 10, 2026 | 286.63M |
| September 09, 2026 | 334.47M |
| September 08, 2026 | 382.31M |
| September 04, 2026 | 408.51M |
| September 03, 2026 | 399.18M |
| September 02, 2026 | 410.89M |
| September 01, 2026 | 380.32M |
| August 31, 2026 | 349.55M |
| August 28, 2026 | 358.29M |
| August 27, 2026 | 372.78M |
| August 26, 2026 | 385.09M |
| August 25, 2026 | 383.30M |
| August 24, 2026 | 382.31M |
| August 21, 2026 | 364.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 205.38B |
| BridgeBio Pharma, Inc. | 17.52B |
| ACADIA Pharmaceuticals, Inc. | 2.662B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 267.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.857M |
| Revenue (Quarterly) | 13.37M |
| Total Expenses (Quarterly) | 17.23M |
| EPS Diluted (Quarterly) | -0.2046 |
| Gross Profit Margin (Quarterly) | 99.85% |
| Profit Margin (Quarterly) | -28.84% |
| Earnings Yield | -0.37% |
| Normalized Earnings Yield | -0.3651 |